Lanean...
Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease [Image: see text]
OBJECTIVES: Depression and antidepressant use, especially selective serotonin reuptake inhibitors (SSRIs), are common in Parkinson disease (PD). The objective of this clinical trial was to assess the efficacy of atomoxetine, a selective norepinephrine reuptake inhibitor (SNRI), for the treatment of...
Gorde:
| Egile Nagusiak: | , , , , , , , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
American Academy of Neurology
2010
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2918470/ https://ncbi.nlm.nih.gov/pubmed/20679638 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/WNL.0b013e3181ebdd79 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|